In our study, for the first time, the FASN inhibitor CER reduced the levels of p-PI3K (a lipid kinase family member), p-AKT, NF-κB p65 active subunit, and TNF-α in human glioma cells (Fig. 5F). This evidence concerns the gene FASN and central nervous system cancer.